Microbix Biosystems Inc
TSX:MBX
Net Margin
Microbix Biosystems Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
|
Microbix Biosystems Inc
TSX:MBX
|
43.7m CAD |
7%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
327.6B USD |
7%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155.7B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
134.5B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
116.4B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.6B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.7B USD |
-11%
|
Microbix Biosystems Inc
Glance View
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm manufactures a range of biological materials for the diagnostics industry, notably antigens (Antigen business) used in immunoassays and its quality assessment and proficiency testing controls (QAPs business). The firm operates in two segments: the development, manufacturing, and sales of antigens as materials for the medical diagnostic industry or as quality assessment products (as finished products) and viral transport medium (VTM) and the development and commercialization of products or technologies such as Kinlytic and . The Kinlyti urokinase, which is a biologic thrombolytic drug used to treat blood clots. The firm's catalogue of catalogue covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted and insect-borne diseases. Its QAPs are available in over 30 countries.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Microbix Biosystems Inc's most recent financial statements, the company has Net Margin of 6.9%.
You don't have any saved screeners yet